缺氧诱导因子1α通过调控miRNA-296-5p影响缺氧诱导的胰腺癌细胞迁移、侵袭

来源 :肿瘤研究与临床 | 被引量 : 0次 | 上传用户:long1024
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:探讨miRNA-296-5p(miR-296-5p)对缺氧诱导的胰腺癌细胞迁移、侵袭的影响及其相关机制。方法:选择人胰腺癌细胞株PANC-1;收集上海市奉贤区中心医院和蚌埠医学院附属第一医院2010年1月至2014年12月55例胰腺癌患者手术切除的胰腺癌组织和10例癌旁正常胰腺组织。采用免疫组织化学及原位杂交法检测胰腺癌及癌旁正常胰腺组织芯片中缺氧诱导因子1α(HIF-1α)、miR-296-5p的表达水平,分析二者的相关性及其与患者临床病理特征的关系。PANC-1细胞分为缺氧组和常氧组,采用Transwell法测定两组细胞迁移与侵袭能力,实时荧光定量聚合酶链反应(qRT-PCR)检测两组细胞miR-296-5p及HIF-1α mRNA表达。转染小干扰RNA(siRNA)干扰HIF-1α的表达,将细胞分为PANC-1组(空白对照)、PANC-1-NC组(阴性对照)、PANC-1-siRNA组,检测miR-296-5p的表达;同时转染miR-296-5p激动剂和抑制剂,分为Agomir-miR-296-5p组(激动剂组)、Agomir-miR-296-5p-NC组(激动剂阴性对照组)、Antagomir-miR-296-5p组(抑制剂组)、Antagomir-miR-296-5p-NC组(抑制剂阴性对照组);Transwell法检测各组细胞迁移和侵袭能力。采用荧光素酶报告基因系统验证miR-296-5p启动子区是否存在HIF-1α的结合位点。结果:胰腺癌组织HIF-1α高表达率高于癌旁正常胰腺组织[81.8%(45/55)比0(0/10),n P<0.01];胰腺癌组织miR-296-5p高表达率低于癌旁正常胰腺组织[12.7%(7/55)比90.0%(9/10),n χ2=27.23,n P<0.01]。HIF-1α表达和miR-296-5p表达呈负相关(n r=-0.53,n P<0.01);miR-296-5p低表达与肿瘤长径、TNM分期、淋巴结转移均有关(均n P<0.05)。常氧组PANC-1侵袭细胞数为(15.3±2.1)个,缺氧组为(24.7±1.5)个,差异有统计学意义(n t=0.26,n P=0.003);常氧组PANC-1迁移细胞数为(20.7±3.8)个,缺氧组为(32.7±1.2)个,差异有统计学意义(n t=5.25,n P=0.006)。常氧组PANC-1细胞HIF-1α mRNA相对表达量为0.30±0.02,缺氧组为1.00±0.01,差异有统计学意义(n t=56.45,n P<0.01);常氧组PANC-1细胞miR-296-5p相对表达量为3.05±0.20,缺氧组为1.14±0.04,差异有统计学意义(n t=16.05,n P<0.01)。PANC-1组、PANC-1-NC组、PANC-1-siRNA组侵袭细胞数分别为(24.7±1.5)个、(25.7±1.5)个、(12.0±1.7)个,差异有统计学意义(n F=68.13,n P<0.01),PANC-1-siRNA组较PANC-1组细胞侵袭能力下降(n t=9.50,n P=0.001);迁移细胞数分别为(32.7±1.2)个、(37.0±1.0)个、(17.3±1.2)个,差异有统计学意义(n F=262.09,n P<0.01),PANC-1-siRNA组较PANC-1组细胞迁移能力下降(n t=16.26,n P<0.01)。Antagomir-miR-296-5p组与PANC-1组比较,细胞侵袭和迁移能力增强(均n P<0.05);Agomir-miR-296-5p组与PANC-1组比较,细胞侵袭和迁移能力减弱(均n P<0.05)。荧光素酶报告基因系统检测荧光素酶活性结果显示,miR-296-5p存在与HIF-1α结合的靶点。n 结论:HIF-1α通过负向调控miR-296-5p在缺氧诱导的胰腺癌细胞的侵袭、迁移中发挥重要作用。“,”Objective:To investigate the effect of miRNA-296-5p (miR-296-5p) on the migration and invasion of hypoxia-induced pancreatic cancer cells and its related mechanisms.Methods:Human pancreatic cancer cell line PANC-1 was selected. Pancreatic cancer tissues from 55 pancreatic cancer patients who underwent the resection and adjacent carcinoma normal pancreatic tissues from 10 patients at Shanghai Fengxian District Central Hospital and Bengbu Medical College First Affiliated Hospital between January 2010 and December 2014 were collected. The expression levels of hypoxia-inducible factor 1α (HIF-1α) and miR-296-5p in tissue microarray of pancreatic cancer and adjacent carcinoma normal pancreatic tissues were detected by using immunohistochemistry and in situ hybridization. The relationship between miR-296-5p and HIF-1α as well as their correlation with clinicopathological characteristics of patients were analyzed. PANC-1 cells were divided into hypoxic group and normoxic group. Transwell assay was used to detect the cell migration and invasion ability of both groups. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to examine the expressions of HIF-1α and miR-296-5p under hypoxic environment of both groups. The expression of HIF-1α was interfered by transfecting small interfering RNA (siRNA). PANC-1 cells were divided into PANC-1 group (the empty control), PANC-1-NC group (the negative control) and PANC-1-siRNA group. The expression of miR-296-5p was measured. After co-transfecting miR-296-5p agonist and miR-296-5p inhibitor, the cells were divided into Agomir-miR-296-5p group (agonist group), Agomir-miR-296-5p-NC group (agonist negative control group), Antagomir-miR-296-5p group (inhibitor group) and Antagomir-miR-296-5p-NC group (inhibitor negative control group). Transwell assay was used to detect the cell migration and invasion ability of all groups. Luciferase reporter gene system was used to verify whether miR-296-5p promoter region had binding site of HIF-1α.Results:The high expression rate of HIF-1α in pancreatic cancer tissues was higher than that of adjacent carcinoma normal pancreatic tissues [81.8% (45/55) vs. 0 (0/10),n P<0.01], and the high expression rate of miR-296-5p in pancreatic cancer tissues was lower than that of adjacent carcinoma normal pancreatic tissues [12.7% (7/55) vs. 90.0% (9/10),n χ2 = 27.23, n P<0.01]. The expression of HIF-1α was negatively correlated with that of miR-296-5p (n r = -0.53, n P<0.01). The low expression of miR-296-5p was closely related with the tumor diameter, TNM staging, lymph node metastasis (alln P<0.05). The number of PANC-1 invasion cell was 15.3±2.1 in normoxic group and 24.7±1.5 in hypoxic group, and the difference was statistically significant (n t = 0.26, n P = 0.003). The number of PANC-1 migration cell was 20.7±3.8 in hypoxic group and 32.7±1.2 in normoxic group, and the difference was statistically significant (n t = 5.25, n P = 0.006). The relative expression level of HIF-1α mRNA in PANC-1 cell of hypoxic group was higher than that of normoxic group [(1.00±0.01) vs. (0.30±0.02)], and the difference was statistically significant (n t = 56.45, n P<0.01); the relative expression level of miR-296-5p in PANC-1 cell of hypoxic group was lower than that of normoxic group [(1.14±0.04) vs. (3.05±0.20)], and the difference was statistically significant (n t = 16.05, n P<0.01). The number of invasion cells in PANC-1 group, PANC-1-NC group and PANC-1-siRNA group was 24.7±1.5, 25.7±1.5, 12.0±1.7, respectively, and the difference was statistically significant (n F = 68.13, n P<0.01).The cell invasion ability in PANC-1-siRNA group was decreased compared with that in PANC-1 group (n t = 9.50, n P = 0.001). The number of cell migration was 32.7±1.2, 37±1.0, 17.3±1.2, respectively in PANC-1 group, PANC-1-NC group and PANC-1-siRNA group, and the difference was statistically significant (n F = 262.09, n P<0.01). The cell migration ability in PANC-1-siRNA group was decreased compared with that in PANC-1 group (n t = 16.26, n P<0.01). The cell invasion and migration ability in Antagomir-miR-296-5p group was increased compared with that in PANC-1 group (alln P<0.05); the cell invasion and migration ability in Agomir-miR-296-5p group was decreased compared with that in PANC-1 group (alln P<0.05). The results of luciferase activity detected by luciferase reporter gene system showed that miR-296-5p had the target binding to HIF-1α.n Conclusions:HIF-1α plays a key role in the invasion and migration of hypoxia-induced pancreatic cancer cells through negatively reducing miR-296-5p.
其他文献
表皮生长因子受体(EGFR)基因作为重要的肿瘤驱动基因,在非小细胞肺癌(NSCLC)的发生、发展中发挥着重要作用。奥希替尼作为最新一代的EGFR酪氨酸激酶抑制剂(TKI)药物,不仅在EGFR敏感突变的患者中取得了显著的效果,在EGFR罕见突变患者中的疗效也令人鼓舞。与以往的EGFR-TKI药物相比,奥希替尼血脑屏障的穿透力强,可以有效防止肺癌脑转移的发生,同时在第一、二代靶向药物出现耐药后,奥希替尼在后续治疗过程中依然有效。文章就EGFR突变的特点、奥希替尼的作用机制及其治疗NSCLC EGFR突变的最新
目的:探讨顺铂序贯重组人血管内皮抑制素胸腔灌注治疗恶性胸腔积液的疗效。方法:选取2018年1月至2021年2月茂名市人民医院收治的80例恶性胸腔积液患者,按随机数字表法分为对照组与研究组,每组各40例。对照组给予小口径导管微创引流联合顺铂胸腔灌注,研究组给予小口径导管微创引流联合顺铂序贯重组人血管内皮抑制素胸腔灌注。比较两组患者疗效、血管内皮生长因子表达、疼痛程度及不良反应情况。结果:研究组治疗有效率高于对照组[90%(36/40)比75%(30/40)],差异有统计学意义(n χ2=5.04,
目的:探讨消癌平注射液联合化疗治疗晚期非小细胞肺癌(NSCLC)患者的临床效果和安全性。方法:基于LinkDoc数据库,纳入2014年至2018年就诊于河南省肿瘤医院等4所医疗中心的首诊为Ⅲn B~Ⅳ期NSCLC的患者1 144例。对入组患者基线资料进行倾向性评分匹配,将患者分为试验组(572例)和对照组(572例),试验组采用消癌平注射液联合化疗,对照组为单纯化疗。观察比较两组患者的客观缓解率(ORR)、疾病控制率(DCR)、总生存(OS)、无进展生存(PFS)、疾病进展时间(TTP)以及不良
目的:探讨血清miRNA-126(miR-126)、miRNA-449a(miR-449a)的表达水平对培美曲塞联合顺铂治疗非小细胞肺癌(NSCLC)的效果和预后的评估作用。方法:回顾性分析2016年1月至2017年1月武汉市汉口医院收治的100例采用培美曲塞联合顺铂治疗的NSCLC患者资料,治疗前通过实时荧光定量聚合酶链反应检测血清中miR-126、miR-449a相对表达水平。以100名同期体检的健康志愿者为健康对照组。治疗2个疗程后进行疗效评估。分析miR-126、miR-449a相对表达水平与患者
目的:探讨表皮生长因子受体(EGFR)基因不同突变状态非小细胞肺癌(NSCLC)患者临床特征及疗效的差异。方法:回顾性分析2018年4月至2020年6月解放军联勤保障部队第九〇四医院收治的324例NSCLC患者的临床资料,采用基因测序法检测EGFR基因及其第19号和第21号外显子突变情况。将EGFR基因突变患者分为EGFR基因第19号外显子突变组(A组)和EGFR基因第21号外显子突变组(B组),均给予吉非替尼联合TP(紫杉醇+顺铂)方案治疗3个月。比较两组临床特征、疗效及不良反应发生情况。结果:234例
维泰醇是从短叶红豆杉树皮的真菌突变株中提取并纯化的单体化合物,维康醇是其氧化物异构体.近期研究表明,二者均具有良好的特异性抗肿瘤活性,可干扰肿瘤细胞中多重信号通路的活性,调控细胞周期相关蛋白表达,引起细胞周期阻滞.维泰醇可特异性作用于黄嘌呤氧化酶,促进细胞内活性氧堆积,激活内源性凋亡通路,导致细胞死亡.蛋白质谱研究表明,维泰醇可特异性地与线粒体三羧酸循环中的4种酶蛋白结合,扰乱线粒体有氧呼吸功能和细胞能量代谢,减少ATP的产生,遏制体内肿瘤生长.维泰醇与维康醇均表现出抑制肿瘤细胞侵袭和迁移的能力,并可诱导
目的:提高对BRAF V600E突变升结肠癌腹膜转移的认识。方法:回顾性分析山西省人民医院收治的1例BRAF V600E突变升结肠癌腹膜转移患者的临床资料,并进行文献复习。结果:该患者为72岁老年男性,肠镜确诊为升结肠癌,基因检测提示BRAF V600E突变,经多学科综合诊疗讨论后给予达拉非尼+曲美替尼+西妥昔单抗联合治疗,经过评估病情,手术切除右半结肠,术后联合腹腔热灌注化疗,达到原发病灶及大网膜转移灶清除、腹膜病灶控制的效果,评价疗效为部分缓解。结论:BRAF V600E突变的晚期结肠癌合并腹膜转移预
目的:探讨儿童心脏肿瘤的临床病理学特征及磁共振成像(MRI)影像学特征。方法:回顾性分析2012年2月至2016年12月于重庆医科大学附属儿童医院经手术病理检查证实的7例心脏肿瘤患儿的临床、病理及MRI影像资料。结果:患儿包括男性3例、女性4例,首诊年龄1个月至3岁。临床表现多有心脏杂音和心界扩大;1例仅表现为急性脑梗死,1例无任何异常表现。病理检查示,6例良性肿瘤(包括纤维瘤2例,横纹肌瘤、黏液瘤、脂肪瘤及血管瘤各1例),1例恶性肿瘤(心包原始神经外胚层肿瘤)。MRI显示,恶性肿瘤在各序列中的信号强度均
免疫系统在肿瘤的发生和发展中起着关键作用.即使阻断免疫检查点在多种肿瘤中均能有效提高抗肿瘤免疫反应,但肿瘤免疫治疗仍面临诸多挑战.三级淋巴结构(TLS)为抗肿瘤细胞的产生和体液免疫应答提供了关键的局部微环境,在多数恶性肿瘤中,TLS的存在与良好的预后相关,但在少数恶性肿瘤中,TLS对患者的预后价值尚存争议.因此,进一步解读TLS与不同肿瘤类型之间的关系可能为开发新型免疫治疗策略提供有益的借鉴.
妊娠相关性乳腺癌因其特殊的生理改变以及治疗可能对胎儿产生影响等因素,在药物治疗上具有一定的复杂性和特殊性.2020年5月,中华医学会外科学分会乳腺外科学组发布妊娠相关性乳腺癌临床诊治专家共识(2020版),推荐蒽环类、紫杉烷类、环磷酰胺、铂类作为妊娠期乳腺癌的治疗药物,但未对其安全性进行分析,也未推荐可行的治疗方案.本文通过回顾既有文献,总结妊娠相关性乳腺癌治疗相关药物对妊娠期、哺乳期患者及胎儿的影响,阐明乳腺癌治疗相关药物在妊娠期、哺乳期的安全性,以期为妊娠期、哺乳期乳腺癌患者的治疗药物选择提供参考.